drugset / Trial / NCT06670222
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
NaSingle-groupOpen-labelTreatment
Summary
Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).
Timeline
- Start
- 2025-07-22
- Primary completion
- 2026-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.1 mg/kg | Oral |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Oral |
| Subject | arsenic trioxide | Small molecule | 0.2 mg/kg | Oral |